Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECMT-154 cream for moderate to severe eczema
ACTRN12621001096842Phase 2Completed
- Sponsor
- Manuka Bioscience
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in atopic dermatitis (AD) comparing ECMT-154 cream with Vehicle control (2 arms). Primary endpoint: Difference in Patient Orientated Eczema Measure (POEM) scores. Started Jan 2022; status: completed.
02
Drugs
ECMT-154
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ACTRN12621001096842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001096842.